Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04420754 · ClinicalTrials.gov registry record · Phase 1
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
A Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer, sponsored by AffyImmune Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 4
- Study locations
NCT04420754: Active Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer, sponsored by AffyImmune Therapeutics.
NCT04420754 is a Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer that is active but no longer recruiting, run by AffyImmune Therapeutics. The registered enrollment target is 70 participants, above the 15-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (367% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04420754, a Phase 1 study of Anaplastic Thyroid Cancer and Relapsed/Refractory Poorly Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by AffyImmune Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
Primary Outcome
The number of Grade 3, 4 and 5 AEs and SAEs that occur throughout the study.
Conditions Studied
Interventions
- BIOLOGICAL AIC100 CAR T Cells
Study Locations (4)
California
- City of Hope National Medical Center, City of Hope Medical Center - Duarte
Illinois
- Northwestern Memorial Hospital - Chicago
New York
- Weill Cornell Medical College - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2030-08-04 |
| Phase | Phase 1 |
What the registry record for NCT04420754 still lists
NCT04420754 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, above the 15-participant average among 5 other Anaplastic Thyroid Cancer trials with a reported enrollment target (367% higher).
The record links to 2 conditions, with Anaplastic Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which AIC100 CAR T Cells is the first listed.
NCT04420754 reports a single indexed study location in California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT04420754 about?
NCT04420754 is a clinical study titled "Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer". The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
What is the current status of trial NCT04420754?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-09-28. Estimated completion is 2030-08-04.
What conditions does trial NCT04420754 study?
This clinical trial studies the following conditions: Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT04420754?
The interventions under investigation include: AIC100 CAR T Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT04420754?
This trial is sponsored by AffyImmune Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04420754 being conducted?
This trial has 4 study locations across California, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
-
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
COMPLETED · Phase 1
-
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
ACTIVE NOT RECRUITING · Early Phase 1
-
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI